Home › Research › Cognitive tests and assessment
Combination of Intranasal insulin and oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk
Hanadi Shamrok, Tal Davidy, Iscka Yore, Tal Niv, Tali C Yaffe, Ramit Ravona‐Springer, Abigail Livny, Orit H. Lesman‐Segev et al.. Alzheimer s & Dementia, 2025-12-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Data collection began in March 2024. So far 562 people completed a pre-screening online questionnaire, with 190 passing pre-screening of whom 54% met eligibility criteria. Of the 73 participants who were screened face-to-face so far, 33% (N = 24) were eligible. Of those deemed ineligible, 44% did not meet criteria for MCI, 44% did not meet criteria of MetS, and 12% did not want to participate. Nineteen participants were randomized, 2 dropped out before beginning treatment and 5 are awaiting randomization. Randomized participants have an average age of 66.7 years [SD=5.26], BMI of 32.8 [SD=5.7], MMSE of 25.0 [SD=2.6] and Hba1c of 5.6 [SD=0.31]; 61% are women. This feasibility study is anticipated to provide the basis for a multi-center large-scale randomized clinical trial investigating the cognitive benefits of the combination of INI and oral semaglutide in individuals with MetS and at high dementia risk. This combination targets multiple pathways implicated in cognitive decline, potentially offering a novel therapeutic approach for the understudied yet highly prevalent and high-risk MetS population.
What this study adds
Evidence grade: High
The record lists 24 participants. This is a feasibility study still collecting data, with only 19 participants randomized so far, testing a combination of intranasal insulin and oral semaglutide in older adults with metabolic syndrome at high dementia risk. No cognitive results are reported yet, so it cannot show whether the combination helps thinking or prevents dementia.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Shamrok, H., Davidy, T., Yore, I., Niv, T., Yaffe, T. C., Ravona‐Springer, R., et al. (2025). Combination of Intranasal insulin and oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk. Alzheimer s & Dementia. https://doi.org/10.1002/alz70860_102127
Vancouver
Shamrok H, Davidy T, Yore I, Niv T, Yaffe TC, Ravona‐Springer R, et al. Combination of Intranasal insulin and oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk. Alzheimer s & Dementia. 2025. doi:10.1002/alz70860_102127. PMID: 41434629.
BibTeX
@article{shamrok2025-41434629,
author = {Shamrok, Hanadi and Davidy, Tal and Yore, Iscka and Niv, Tal and Yaffe, Tali C and Ravona‐Springer, Ramit and Livny, Abigail and Lesman‐Segev, Orit H. and others},
title = {{Combination of Intranasal insulin and oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70860_102127},
pmid = {41434629},
url = {https://doi.org/10.1002/alz70860_102127}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- So far 562 people completed a pre-screening online questionnaire, with 190 passing pre-screening of whom 54% met eligibility criteria.
- Of the 73 participants who were screened face-to-face so far, 33% (N = 24) were eligible.
- Of those deemed ineligible, 44% did not meet criteria for MCI, 44% did not meet criteria of MetS, and 12% did not want to participate.
- Nineteen participants were randomized, 2 dropped out before beginning treatment and 5 are awaiting randomization.
- Randomized participants have an average age of 66.7 years [SD=5.26], BMI of 32.8 [SD=5.7], MMSE of 25.0 [SD=2.6] and Hba1c of 5.6 [SD=0.31]; 61% are women.
Why it matters
This is a feasibility study still collecting data, with only 19 participants randomized so far, testing a combination of intranasal insulin and oral semaglutide in older adults with metabolic syndrome at high dementia risk. No cognitive results are reported yet, so it cannot show whether the combination helps thinking or prevents dementia.
Study details
- Participants24
- Evidence strengthHigh
How this study scored 45/100
Published in a peer-reviewed journal. Scored zero for study design and effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 24 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 1 / 6 | Cited 0.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Michal Schnaider Beeri: h-index 52 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Icahn School of Medicine at Mount Sinai: institution h-index 1,331 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41434629) |
| Free to read | 2 / 2 | Free to read |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70860_102127
- PubMed: 41434629
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Cognitive tests and assessment from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.